all report title image

NOVEL DRUGS AND DEVICES TO LOWER INTRAOCULAR PRESSURE MARKET ANALYSIS

Novel Drugs and Devices to Lower Intraocular Pressure Market, by Treatment Type (Drug (Rhopressa, Roclatan, Xelpros, Vyzulta and Others) and Device (Implant, Therapeutic Ultrasound and Others), by Distribution Channel (Hospitals & Clinics, Retail Channel and Online Channels), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Nov 2024
  • Code : CMI2670
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Market Challenges And Opportunities

Global Novel Drugs and Devices to Lower Intraocular Pressure Market Restraints

Side effects of glaucoma medications are expected to hinder growth of the global novel drugs and devices to lower intraocular pressure market. Side effects of medications used for the treatment of glaucoma, such as Rhopressa, include internal bleeding, corneal deposits, and stinging. Also, the cost of these medications is very high. For instance, 2.5 milliliter’s of Rhopressa (Netarsudil ophthalmic solution) costs around US$269. Hence, these factors are expected to restrain the global novel drugs and devices to lower intraocular pressure market growth.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.